Form 4: Armata Pharmaceuticals CEO Deborah Birx Reports Stock Disposals for Tax Obligations

Deborah Birx, CEO of Armata Pharmaceuticals, reports disposing of shares to cover income tax obligations related to the settlement of restricted stock units.

Summary

• Deborah Birx, the CEO of Armata Pharmaceuticals, filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On July 10, 2024, she disposed of 22,925 shares of common stock at a price of $2.68 per share to satisfy income tax obligations.
• On March 14, 2025, she disposed of 6,061 shares of common stock at a price of $1.95 per share to satisfy income tax obligations.
• Following these transactions, Birx directly owns 231,014 shares of Armata Pharmaceuticals.
• The disposals were related to the net settlement of restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock disposals for tax purposes, a routine activity.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The stock disposal may have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates

Keywords

Form 4, Beneficial Ownership, Deborah Birx, Armata Pharmaceuticals, ARMP, Stock Disposal, Tax Obligations, Restricted Stock Units